Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) - MOVE-Lp(a) - Eli Lilly and CompanySee more
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) - ATTAIN-Outcomes - Eli Lilly and CompanySee more
Elevated Lipoprotein A
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) - MOVE-Lp(a) - Eli Lilly and CompanySee more
Renal disease
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) - ATTAIN-Outcomes - Eli Lilly and CompanySee more
Heart failure
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity - MARITIME-HF - AmgenSee more
Obesity
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity - MARITIME-HF - AmgenSee more